Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDY -2.22%74 Cash Ratio is 0.20 as of Dec. 2025, which is 20% below its 10-year median of 0.25. GuruFocus rates SHTDY with a GF Score™ of 74/100 and a GF Value™ of $13.60 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 117 Medical Distribution companies, Sinopharm Group Co ranks worse than 50.43% on this metric.
Sinopharm Group Co has a Cash Ratio of 0.20. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Sinopharm Group Co's Cash Ratio or its related term are showing as below:
SHTDY'
s Cash Ratio Range Over the Past 10 Years
Min: 0.2 Med: 0.25 Max: 0.26
Current: 0.2
During the past 13 years, Sinopharm Group Co's highest Cash Ratio was 0.26. The lowest was 0.20. And the median was 0.25.
SHTDY's Cash Ratio is ranked worse than 50.43% of 117
companies
in the Medical Distribution industry
Industry Median: 0.2
vs SHTDY: 0.20
Sinopharm Group Co (OTCPK:SHTDY) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Sinopharm Group Co Cash Ratio Related Terms
Sinopharm Group Co Cash Ratio Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinopharm Group Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Cash Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (SHTDY) has a Cash Ratio of 0.20 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Sinopharm Group Co and its competitors. This is 20% below median its historical median of 0.25. Over the past decade, Sinopharm Group Co's Cash Ratio has ranged from 0.20 to 0.26. According to the industry distribution chart, Sinopharm Group Co ranks #59 out of 117 companies in the Medical Distribution industry, placing it in the top 50.4%.
Is Sinopharm Group Co's Cash Ratio too high?
Sinopharm Group Co's current Cash Ratio of 0.20 is 20% below median its 10-year median of 0.25. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 0.26. The Medical Distribution industry median Cash Ratio is 0.20. Sinopharm Group Co's value of 0.20 is 0% at this industry median. Based on the distribution chart, Sinopharm Group Co ranks #59 out of 117 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Cash Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #59 out of 117 companies for Cash Ratio. This places Sinopharm Group Co in the lower half of its industry. The industry median Cash Ratio is 0.20. Sinopharm Group Co's value of 0.20 is 0% at this benchmark. Historically, Sinopharm Group Co's own Cash Ratio has ranged from 0.20 to 0.26 over the past decade. While the company's 10-year median is 0.25 vs. the industry median of 0.20, Sinopharm Group Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Distribution company?
The median Cash Ratio among Medical Distribution companies is 0.20, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Cash Ratio of 0.20 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Cash Ratio is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Cash Ratio is 0.20, which is 20% below median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.60, compared to a current price of $10.99 — trading 19.2% below its estimated fair value. The current Cash Ratio is 0.20, which is 20% below median its 10-year median of 0.25 and 0% at the Medical Distribution industry median of 0.20. Sinopharm Group Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Cash Ratio is 0.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDY) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $10.99 is trading 19.2% below its estimated GF Value™ of $13.60.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDY:
Cash Ratio: 0.20 (20% below median its 10-year median of 0.25)
GF Value™: $13.60 vs. price of $10.99 (19.2% below fair value)
Industry Position: 0% at the Medical Distribution median (#59 of 117)
No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
74GF Score
Get the complete analysis for SHTDY
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDY has been successfully added to your 
